Treatment Information

Back

Liver Cancer treatment details. Biologic therapy.

Kinki University School of Medicine, Osaka-Sayama, Japan.

Survival: monthsCountry:Japan
Toxiciy Grade:4City/State/Province:Osaka-Sayama
Treatments:Biologic therapyHospital:Kinki University School of Medicine
Drugs:Journal:Link
Date:Sep 2011

Description:

Patients:
This phase III involved 229 hepatocellular carcinoma (HCC) patients who had been previously treated with epirubicin, cisplatin, doxorubicin, and/or mitomycin. The median patient age was 69 years and 76% were male.

Treatment:
Patients were treated with the biologic therapy agent called sorafenib, which is a kinase inhibitor that interferes with cancer cell growth.

Toxicities:
The most severe adverse events were of grade 4 and included liver chemistry effects and thrombocytopenia. Hand-foot skin reactions, alopecia, diarrhea, and hypertension were also reported.

Results:
The reported median overall survival was 29.7 months.

Support:
This study was funded by Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals.

Correspondence: Dr. Masatoshi Kudo; email: [email protected]



Back